A Phase 3 interventional study of zoster vaccine live (ZOSTAVAX™) and Comparator: Placebo in Herpes Zoster, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-01-26.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing Chickenpox Vaccine in Herpes Zoster — none open to participants now, none under way, none of them phase 3. Chickenpox Vaccine · Herpes Zoster.
Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, this one is the 17th largest by enrollment, is the only one that started in 2006, is one of 9 in phase 3, and was the 3rd registered.
299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.
Browse Herpes Zoster studies →None of the 29 studies testing Chickenpox Vaccine in Herpes Zoster is open now. The open studies under Herpes Zoster, anywhere →
Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 9 · Phase 4 8
First in 2001; this study’s year is marked. 1 started in 2006.
This study's enrollment of 101 is below the median of 160 across 247 interventional studies indexed under Herpes Zoster.
Median enrollment 160 across the 29 interventional studies. Of the 28 that completed or were terminated, 20 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
27 studies in Herpes Zoster by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 26 finished, 24 (92%) have results posted.
Among the 27 studies in Herpes Zoster by Merck & Co., Inc, this one is the 22nd largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2006, is one of 14 in phase 3, and was the 4th registered.
Merck & Co., Inc’s Herpes Zoster studies by the year they started, since 1995.
None of the studies under way reaches primary completion within a year.
Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 27 in Herpes Zoster:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether the investigational zoster vaccine, is generally well tolerated when administered to participants with a history of herpes zoster.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Zoster vaccine live on Day 1 (Period 1), placebo on Week 4 (Period 2)
Biological: zoster vaccine live (ZOSTAVAX™) · Biological: Comparator: Placebo
Placebo on Day 1 (Period 1), zoster vaccine live on Week 4 (Period 2)
Biological: zoster vaccine live (ZOSTAVAX™) · Biological: Comparator: Placebo
1 dose 0.65 mL/dose subcutaneous injection of zoster vaccine live
Also known as: Zostavax
1 dose 0.65 mL/dose subcutaneous injection of placebo.
Vaccine-related Serious Adverse Experiences (SAEs) for 28 Days Postvaccination
SAEs are AEs at any dose that: Results in death or persistent/significant disability/incapacity; or prolongs an existing inpatient hospitalization or Is life threatening; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose or Is an other important medical event
Time frame: To Day 28 postvaccination
Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Antibody Responses at 4 Weeks Postvaccination
The GMT of the VZV-specific antibody responses as measured by gpELISA (glycoprotein enzyme-linked immunosorbent assay) at the prespecified day ranges at prevaccination and 4 weeks postvaccination
Time frame: 4 weeks postvaccination
Geometric Mean Fold Rise (GMFR) in VZV Antibody Titers From Prevaccination to 4 Weeks Postvaccination
GMFR of the VZV antibody response at the prespecified day ranges prevaccination and 4 weeks postvaccination
Time frame: From prevaccination (baseline) to 4 weeks postvaccination
Patients were recruited at 9 sites in the United States. First patient enrolled: May-2006; Last patient last visit: July - 2007
| Milestone | ZOSTAVAX™ / Placebo | Placebo / ZOSTAVAX™ |
|---|---|---|
| Started | 51 | 50 |
| Completed | 51 | 50 |
| Not completed | 0 | 0 |
| Milestone | ZOSTAVAX™ / Placebo | Placebo / ZOSTAVAX™ |
|---|---|---|
| Started | 51 | 49 |
| Completed | 51 | 49 |
| Not completed | 0 | 0 |
SAEs are AEs at any dose that: Results in death or persistent/significant disability/incapacity; or prolongs an existing inpatient hospitalization or Is life threatening; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose or Is an other important medical event
| Participants | ZOSTAVAX™ | Placebo |
|---|---|---|
| With Vaccine-related SAEs | 0 | 0 |
| Without Vaccine-related SAEs | 100 | 101 |
The GMT of the VZV-specific antibody responses as measured by gpELISA (glycoprotein enzyme-linked immunosorbent assay) at the prespecified day ranges at prevaccination and 4 weeks postvaccination
| gpELISA units/mL | ZOSTAVAX™ | Placebo |
|---|---|---|
| Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Antibody Responses at 4 Weeks Postvaccination | 810.1 (688.3 to 953.4) | 391.1 (291.9 to 523.9) |
GMFR of the VZV antibody response at the prespecified day ranges prevaccination and 4 weeks postvaccination
| Geometric mean fold rise | ZOSTAVAX™ | Placebo |
|---|---|---|
| Geometric Mean Fold Rise (GMFR) in VZV Antibody Titers From Prevaccination to 4 Weeks Postvaccination | 2.1 (1.8 to 2.4) | 1.0 (0.9 to 1.1) |
Collected over Day 1 - 28 following each vaccination. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ZOSTAVAX™ | — | 0/98 (0%) | 45/98 (45.9%) |
| Placebo | — | 0/96 (0%) | 4/96 (4.2%) |
| Event | ZOSTAVAX™ | Placebo |
|---|---|---|
| Injection Site PainGeneral disorders | 36/98 | 1/96 |
| Injection Site ErythemaGeneral disorders | 33/98 | 3/96 |
| Injection Site SwellingGeneral disorders | 26/98 | 2/96 |
| Injection Site PruritusGeneral disorders | 5/98 | 0/96 |
| Age, Customized(participants) | ZOSTAVAX™ / Placebo | Placebo / ZOSTAVAX™ | Total |
|---|---|---|---|
| 50 to 59 Years of age | 10 | 10 | 20 |
| ≥ 60 Years of age | 41 | 40 | 81 |
| Sex: Female, Male(Participants) | ZOSTAVAX™ / Placebo | Placebo / ZOSTAVAX™ | Total |
|---|---|---|---|
| Female | 36 | 24 | 60 |
| Male | 15 | 26 | 41 |
| Race/Ethnicity, Customized(participants) | ZOSTAVAX™ / Placebo | Placebo / ZOSTAVAX™ | Total |
|---|---|---|---|
| Asian | 1 | 3 | 4 |
| Black | 3 | 3 | 6 |
| Hispanic American | 0 | 2 | 2 |
| White | 47 | 42 | 89 |
No study locations are listed for this record.
The record gives a start of May 2006, a primary completion of Jul 2007 and a completion of Jul 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2010, 3 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Chickenpox Vaccine